IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s What Happened

IPSEN (OTCMKTS:IPSEY)’s stock price gapped down prior to trading on Friday. The stock had previously closed at $42.4080, but opened at $40.6550. IPSEN shares last traded at $40.6550, with a volume of 1,408 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

IPSEN Trading Down 3.1%

The stock has a 50-day moving average price of $46.15 and a 200 day moving average price of $46.59.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.